AU2013371025B2 - Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders - Google Patents

Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders Download PDF

Info

Publication number
AU2013371025B2
AU2013371025B2 AU2013371025A AU2013371025A AU2013371025B2 AU 2013371025 B2 AU2013371025 B2 AU 2013371025B2 AU 2013371025 A AU2013371025 A AU 2013371025A AU 2013371025 A AU2013371025 A AU 2013371025A AU 2013371025 B2 AU2013371025 B2 AU 2013371025B2
Authority
AU
Australia
Prior art keywords
pregn
administration
depressive disorder
nasal
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013371025A
Other languages
English (en)
Other versions
AU2013371025A1 (en
Inventor
Louis Monti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pherin Pharmaceuticals Inc
Original Assignee
Pherin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Pharmaceuticals Inc filed Critical Pherin Pharmaceuticals Inc
Publication of AU2013371025A1 publication Critical patent/AU2013371025A1/en
Application granted granted Critical
Publication of AU2013371025B2 publication Critical patent/AU2013371025B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013371025A 2012-12-28 2013-12-19 Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders Active AU2013371025B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747167P 2012-12-28 2012-12-28
US61/747,167 2012-12-28
PCT/US2013/076497 WO2014105620A1 (en) 2012-12-28 2013-12-19 Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders

Publications (2)

Publication Number Publication Date
AU2013371025A1 AU2013371025A1 (en) 2015-07-09
AU2013371025B2 true AU2013371025B2 (en) 2018-01-18

Family

ID=49950051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013371025A Active AU2013371025B2 (en) 2012-12-28 2013-12-19 Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders

Country Status (11)

Country Link
US (1) US10322138B2 (enExample)
EP (1) EP2938346B1 (enExample)
JP (1) JP6283689B2 (enExample)
KR (1) KR102209475B1 (enExample)
CN (1) CN104936600B (enExample)
AU (1) AU2013371025B2 (enExample)
CA (1) CA2894686C (enExample)
DK (1) DK2938346T3 (enExample)
ES (1) ES2625778T3 (enExample)
MX (1) MX369774B (enExample)
WO (1) WO2014105620A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
ES2972282T3 (es) * 2019-04-15 2024-06-12 Vistagen Therapeutics Inc Tratamiento de la migraña
WO2024254005A1 (en) 2023-06-04 2024-12-12 Vistagen Therapeutics, Inc. 1,3,5(10),16-estratetraen-3-yl acetate for use in improving psychomotor or cognitive performance
US20250312356A1 (en) * 2024-04-08 2025-10-09 Vistagen Therapeutics, Inc. Treatment of dysmenorrhea

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028904A1 (en) * 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US20020123138A1 (en) * 2000-11-30 2002-09-05 Jian Zhang Human VNO receptor (R1)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5303703A (en) 1991-10-03 1994-04-19 Pherin Corporation Combined neuroepithelial sample delivery electrode device and methods of using same
US6066627A (en) 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US5994333A (en) 1994-08-04 1999-11-30 Pherin Corporation Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6117860A (en) 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US6331534B1 (en) 1994-08-04 2001-12-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate pain
JP4450435B2 (ja) * 1996-07-23 2010-04-14 フィーリン・ファーマシューティカルズ・インコーポレイテッド Ｐｍｓおよび不安の症状を緩和する、ｖｎｏにおける神経化学刺激物質としてのステロイド
US20030045514A1 (en) 2001-05-03 2003-03-06 Louis Monti 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028904A1 (en) * 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6057439A (en) * 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US20020123138A1 (en) * 2000-11-30 2002-09-05 Jian Zhang Human VNO receptor (R1)

Also Published As

Publication number Publication date
CA2894686A1 (en) 2014-07-03
CN104936600B (zh) 2018-08-03
EP2938346A1 (en) 2015-11-04
KR20150100884A (ko) 2015-09-02
MX369774B (es) 2019-11-21
WO2014105620A1 (en) 2014-07-03
CN104936600A (zh) 2015-09-23
EP2938346B1 (en) 2017-04-05
MX2015008454A (es) 2016-05-16
CA2894686C (en) 2021-05-04
US20140187524A1 (en) 2014-07-03
HK1210421A1 (en) 2016-04-22
JP2016504361A (ja) 2016-02-12
DK2938346T3 (en) 2017-06-12
AU2013371025A1 (en) 2015-07-09
KR102209475B1 (ko) 2021-01-28
ES2625778T3 (es) 2017-07-20
JP6283689B2 (ja) 2018-02-21
US10322138B2 (en) 2019-06-18

Similar Documents

Publication Publication Date Title
AU2013371025B2 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders
EP2694065B1 (en) Composition for treating hypoactive sexual desire disorder
HK1210421B (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders
US8722652B2 (en) Acute treatment of social phobia
AU2020259269B2 (en) Treatment of migraine
US20250312356A1 (en) Treatment of dysmenorrhea
US20240165049A1 (en) Methods and compositions for treatment of low circulating testosterone conditions
WO2024254005A1 (en) 1,3,5(10),16-estratetraen-3-yl acetate for use in improving psychomotor or cognitive performance
HK40068177B (en) Treatment of migraine
HK40068177A (en) Treatment of migraine
KR20220019715A (ko) 만성 기침의 치료를 위한 [((1r,2s,5r)-2-이소프로필-5-메틸-사이클로헥산카르보닐)-아미노]-아세트산 이소프로필 에스테르

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)